Epigenomics AG (LON: 0QXH)
London
· Delayed Price · Currency is GBP · Price in EUR 1.110
0.00 (0.00%)
At close: Dec 23, 2024
Epigenomics AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.14 | 0.34 | 0.9 | 6.2 | 0.84 | 1.13 | Upgrade
|
| Revenue Growth (YoY) | -69.52% | -62.27% | -85.51% | 636.70% | -25.16% | -26.61% | Upgrade
|
| Cost of Revenue | 0.01 | 0.06 | 0.47 | 0.14 | 0.15 | 0.25 | Upgrade
|
| Gross Profit | 0.12 | 0.28 | 0.43 | 6.07 | 0.7 | 0.87 | Upgrade
|
| Selling, General & Admin | -2.48 | 4.21 | 3 | 7.51 | 7.3 | 8.94 | Upgrade
|
| Research & Development | -1.45 | - | - | 3.11 | 3.66 | 7.34 | Upgrade
|
| Other Operating Expenses | -0.69 | -0.32 | 8.8 | -0.39 | -0.15 | -0.3 | Upgrade
|
| Operating Expenses | -4.04 | 4.46 | 12.15 | 10.23 | 10.81 | 15.97 | Upgrade
|
| Operating Income | 4.16 | -4.18 | -11.73 | -4.16 | -10.11 | -15.1 | Upgrade
|
| Interest Expense | -0.04 | - | -0.08 | -0.05 | -0.06 | -0.06 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.04 | 0.09 | 0.01 | 0.02 | 0.17 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.29 | -0.09 | 0.72 | 1.82 | -1.51 | 0.43 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | -0.02 | -0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | 3.84 | -4.23 | -11 | -2.4 | -11.66 | -14.57 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.41 | -0.23 | -6.31 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.01 | - | -0 | Upgrade
|
| Pretax Income | 2.96 | -4.46 | -17.3 | -2.41 | -11.66 | -14.57 | Upgrade
|
| Income Tax Expense | -0 | - | - | 0.02 | 0.02 | 2.45 | Upgrade
|
| Net Income | 2.96 | -4.46 | -17.3 | -2.43 | -11.69 | -17.02 | Upgrade
|
| Net Income to Common | 2.96 | -4.46 | -17.3 | -2.43 | -11.69 | -17.02 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 4.72% | 4.93% | 45.14% | 93.94% | 24.03% | 37.96% | Upgrade
|
| EPS (Basic) | 3.39 | -5.23 | -21.28 | -4.33 | -40.45 | -73.06 | Upgrade
|
| EPS (Diluted) | 3.39 | -5.23 | -21.28 | -4.33 | -40.45 | -73.06 | Upgrade
|
| Free Cash Flow | - | -5.71 | -10.71 | -4.19 | -9.58 | -13.58 | Upgrade
|
| Free Cash Flow Per Share | - | -6.70 | -13.17 | -7.47 | -33.16 | -58.30 | Upgrade
|
| Gross Margin | 89.79% | 83.22% | 47.27% | 97.81% | 82.78% | 77.51% | Upgrade
|
| Operating Margin | 3054.06% | -1231.19% | -1304.56% | -67.10% | -1201.19% | -1342.40% | Upgrade
|
| Profit Margin | 2176.13% | -1315.79% | -1924.81% | -39.14% | -1387.89% | -1512.89% | Upgrade
|
| Free Cash Flow Margin | - | -1684.42% | -1191.77% | -67.50% | -1137.89% | -1207.20% | Upgrade
|
| EBITDA | 3.16 | -3.61 | -4.71 | -4.06 | -10.01 | -14.97 | Upgrade
|
| EBITDA Margin | 2322.57% | - | - | -65.40% | - | - | Upgrade
|
| D&A For EBITDA | -1 | 0.56 | 7.02 | 0.11 | 0.11 | 0.13 | Upgrade
|
| EBIT | 4.16 | -4.18 | -11.73 | -4.16 | -10.11 | -15.1 | Upgrade
|
| EBIT Margin | 3054.06% | - | - | -67.10% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.